Analysis reveals metabolic changes in retinoblastoma tumors, suggesting serum metabolites as potential biomarkers of tumor activity and treatment response.
The serum metabolic profile changes based on tumor status (active versus regressed). Serum metabolites may serve as a prognostic biomarker suggestive of tumor activity and response to treatment.
No takes yet. Share an insight, caveat, or question.
Gulati et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: